Expression of pDC-associated molecules in pDC neoplasms and in myeloid and lymphoid leukemias
| . | pDC neoplasms . | Leukemia cutis . | CML . | CMML . | B-ALL . | T-ALL . | |
|---|---|---|---|---|---|---|---|
| Hematodermic . | Myeloproliferative associated . | ||||||
| Transcription factors | |||||||
| BCL11A | 39 of 39 (100) | 3 of 5 (60) | 6i of 24 (25) | 1 of 7 (14) | 3 of 5 (60) | 7w of 7 (100) | 4 of 5 (80) |
| E47 | 16a of 16 (100) | 2h of 3 (67) | 20j of 24 (83) | 5 of 6 (83) | 5 of 5 (100) | 7 of 7 (100) | 6 of 6 (100) |
| FOXP1 | 6 of 6 (100) | 2 of 2 (100) | 7 of 7 (100) | 1 of 5 (20) | 1 of 4 (25) | nd | nd |
| ICSBP/IRF8 | 33b of 33 (100) | 1 of 3 (33) | 5k of 24l (21) | 0 of 5 (0) | 0 of 5 (0) | 0 of 6 (0) | 0 of 6 (0) |
| PU.1 | 5c of 16 (31) | 3 of 3 (100) | 19m of 24 (79) | 5 of 5 (100) | 5 of 5 (100) | 2 of 7 (28) | 0 of 6 (0) |
| Signaling molecules | |||||||
| BLNK | 21 of 21 (100) | 4 of 4 (100) | 8n of 24o (33) | 0 of 6 (0) | 0 of 5 (0) | 7 of 7 (100) | 1 of 6 (17) |
| BTK | 16 of 16 (100) | 3 of 3 (100) | 24 of 24 (100) | 1 of 6 (17) | 2 of 4 (50) | 7 of 7 (100) | 0 of 6 (0) |
| CD2AP | 35 of 37 (95) | 6 of 6 (100) | 1 of 24 (4) | 0 of 7 (0) | 0 of 5 (0) | 0 of 7 (0) | 0 of 5x (0) |
| DAP12 | 13 of 13 (100) | 2 of 2 (100) | 20 of 22p (91) | 5 of 5 (100) | 3 of 4 (75) | 0 of 7 (0) | 0 of 5 (0) |
| IRAK1 | 6d of 6 (100) | 1 of 1 (100) | 6q of 7 (86) | 1 of 5t (20) | 3u of 4 (75) | nd | nd |
| Lyn | 16 of 16 (100) | 2 of 2 (100) | 23r of 24 (96) | 5 of 5 (100) | 2 of 5v (40) | 6 of 7 (86) | 0 of 6 (0) |
| Syk | 16e of 16 (100) | 1 of 1 (100) | 24 of 24 (100) | 5 of 5 (100) | 5 of 5 (100) | 7 of 7 (100) | 3 of 6 (50) |
| TCB1D4 | 2 of 4 (50) | 1 of 1 (100) | 3 of 7 (43) | 0 of 5 (0) | 0 of 4 (0) | nd | nd |
| Receptor molecules | |||||||
| CD79b | 9f of 15 (60) | 0 of 2 (0) | 3 of 24 (12.5) | 0 of 5 (0) | 0 of 5 (0) | 6 of 7 (86) | 1 of 6 (17) |
| TLR7 | 16 of 16 (100) | 3 of 3 (100) | 22 of 24 (92) | 1 of 6 (17) | 0 of 4 (0) | 2 of 7 (28) | 0 of 6 (0) |
| TLR9 | 10g of 14 (71) | 1 of 2 (50) | 24s of 24 (100) | 0 of 5 (0) | 4 of 4 (100) | 0 of 7 (0) | 2 of 5 (40) |
| . | pDC neoplasms . | Leukemia cutis . | CML . | CMML . | B-ALL . | T-ALL . | |
|---|---|---|---|---|---|---|---|
| Hematodermic . | Myeloproliferative associated . | ||||||
| Transcription factors | |||||||
| BCL11A | 39 of 39 (100) | 3 of 5 (60) | 6i of 24 (25) | 1 of 7 (14) | 3 of 5 (60) | 7w of 7 (100) | 4 of 5 (80) |
| E47 | 16a of 16 (100) | 2h of 3 (67) | 20j of 24 (83) | 5 of 6 (83) | 5 of 5 (100) | 7 of 7 (100) | 6 of 6 (100) |
| FOXP1 | 6 of 6 (100) | 2 of 2 (100) | 7 of 7 (100) | 1 of 5 (20) | 1 of 4 (25) | nd | nd |
| ICSBP/IRF8 | 33b of 33 (100) | 1 of 3 (33) | 5k of 24l (21) | 0 of 5 (0) | 0 of 5 (0) | 0 of 6 (0) | 0 of 6 (0) |
| PU.1 | 5c of 16 (31) | 3 of 3 (100) | 19m of 24 (79) | 5 of 5 (100) | 5 of 5 (100) | 2 of 7 (28) | 0 of 6 (0) |
| Signaling molecules | |||||||
| BLNK | 21 of 21 (100) | 4 of 4 (100) | 8n of 24o (33) | 0 of 6 (0) | 0 of 5 (0) | 7 of 7 (100) | 1 of 6 (17) |
| BTK | 16 of 16 (100) | 3 of 3 (100) | 24 of 24 (100) | 1 of 6 (17) | 2 of 4 (50) | 7 of 7 (100) | 0 of 6 (0) |
| CD2AP | 35 of 37 (95) | 6 of 6 (100) | 1 of 24 (4) | 0 of 7 (0) | 0 of 5 (0) | 0 of 7 (0) | 0 of 5x (0) |
| DAP12 | 13 of 13 (100) | 2 of 2 (100) | 20 of 22p (91) | 5 of 5 (100) | 3 of 4 (75) | 0 of 7 (0) | 0 of 5 (0) |
| IRAK1 | 6d of 6 (100) | 1 of 1 (100) | 6q of 7 (86) | 1 of 5t (20) | 3u of 4 (75) | nd | nd |
| Lyn | 16 of 16 (100) | 2 of 2 (100) | 23r of 24 (96) | 5 of 5 (100) | 2 of 5v (40) | 6 of 7 (86) | 0 of 6 (0) |
| Syk | 16e of 16 (100) | 1 of 1 (100) | 24 of 24 (100) | 5 of 5 (100) | 5 of 5 (100) | 7 of 7 (100) | 3 of 6 (50) |
| TCB1D4 | 2 of 4 (50) | 1 of 1 (100) | 3 of 7 (43) | 0 of 5 (0) | 0 of 4 (0) | nd | nd |
| Receptor molecules | |||||||
| CD79b | 9f of 15 (60) | 0 of 2 (0) | 3 of 24 (12.5) | 0 of 5 (0) | 0 of 5 (0) | 6 of 7 (86) | 1 of 6 (17) |
| TLR7 | 16 of 16 (100) | 3 of 3 (100) | 22 of 24 (92) | 1 of 6 (17) | 0 of 4 (0) | 2 of 7 (28) | 0 of 6 (0) |
| TLR9 | 10g of 14 (71) | 1 of 2 (50) | 24s of 24 (100) | 0 of 5 (0) | 4 of 4 (100) | 0 of 7 (0) | 2 of 5 (40) |
Cases are scored as positive if at least 90% of neoplastic cells were stained. In the footnotes below, ″weak and/or weakly positive″ indicates a low level of staining by all neoplastic cells. Data are numbers (%).
4 of 16 were weakly positive.
2 of 33 were weakly positive.
1 of 5 was very weakly positive.
2 of 6 were weakly positive.
2 of 16 were weakly positive.
3 of 9 were weakly positive.
2 of 10 were very weakly positive.
1 of 2 was weakly positive.
3 of 6 were weakly positive.
6 of 20 were weakly positive.
2 of 5 were weakly positive.
In 3 of 24 cases (scored as negative) a small proportion of atypical cells were positive.
1 of 19 was weakly positive.
3 of 8 were very weakly positive.
In 2 of 24 cases (scored as negative) a small proportion of atypical cells were positive.
In 2 of 22 cases (scored as negative) a small proportion of tumor cells were positive.
2 of 6 cases were weakly positive.
1 of 23 was weakly positive.
3 of 24 were weakly positive.
In 1 of 5 cases (scored as negative) a small proportion of cells was weakly positive.
All 3 cases were weakly positive.
In 3 of 5 cases (scored as negative) 5% to 20% of cells were positive.
1 of 7 was very weakly positive.
1 of 5 cases showed focal and weak positivity.